A detailed history of Vanguard Group Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 9,737,254 shares of PCVX stock, worth $735 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,737,254
Previous 8,452,371 15.2%
Holding current value
$735 Million
Previous $531 Million 25.31%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$59.79 - $81.05 $76.8 Million - $104 Million
1,284,883 Added 15.2%
9,737,254 $665 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $7.62 Million - $10.7 Million
168,125 Added 2.03%
8,452,371 $531 Million
Q3 2023

Nov 14, 2023

BUY
$46.0 - $53.1 $2.2 Million - $2.54 Million
47,872 Added 0.58%
8,284,246 $422 Million
Q2 2023

Aug 14, 2023

BUY
$34.66 - $54.07 $59.1 Million - $92.1 Million
1,704,058 Added 26.09%
8,236,374 $411 Million
Q1 2023

May 15, 2023

SELL
$36.27 - $47.2 $2.95 Million - $3.84 Million
-81,350 Reduced 1.23%
6,532,316 $245 Million
Q4 2022

Feb 10, 2023

BUY
$20.58 - $47.95 $44.5 Million - $104 Million
2,161,521 Added 48.55%
6,613,666 $317 Million
Q3 2022

Nov 14, 2022

BUY
$21.69 - $28.53 $10.8 Million - $14.2 Million
496,227 Added 12.54%
4,452,145 $107 Million
Q2 2022

Aug 12, 2022

BUY
$17.68 - $26.58 $5.77 Million - $8.68 Million
326,554 Added 9.0%
3,955,918 $86.1 Million
Q1 2022

May 13, 2022

BUY
$17.46 - $26.36 $8.64 Million - $13.1 Million
495,078 Added 15.8%
3,629,364 $87.6 Million
Q4 2021

Feb 14, 2022

BUY
$19.32 - $26.45 $1.75 Million - $2.39 Million
90,404 Added 2.97%
3,134,286 $74.6 Million
Q3 2021

Nov 12, 2021

BUY
$20.26 - $26.97 $3.96 Million - $5.27 Million
195,238 Added 6.85%
3,043,882 $77.2 Million
Q2 2021

Aug 13, 2021

BUY
$16.45 - $24.06 $46.9 Million - $68.5 Million
2,848,644 New
2,848,644 $64.1 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $4.48B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.